Table 1 Key Inputs in the Model

Event rate per 100 patient-years, PEACE population with AMI

 Nonfatal MI

1.7

NA

NA

[21]

 Nonfatal stroke

0.9

NA

NA

 Cardiovascular-related death

2.2

NA

NA

 All-cause mortality

3.1

NA

NA

 Coronary revascularization

6.4

NA

NA

Event rate per 100 patient-years, trial population of FOURIER trial

 Nonfatal MI

2.5

2.2–2.7

Lognormal

[7]

 Nonfatal stroke

0.9

0.8–1.1

Lognormal

 Cardiovascular-related death

0.8

0.7–1.0

Lognormal

 Coronary revascularization

3.9

3.6–4.3

Lognormal

Intervention effect, hazard ratio

 Nonfatal MI (year 1)

0.79

0.67–0.93

Lognormal

[7, 24]

 Nonfatal MI (beyond 1y)

0.64

0.54–0.76

Lognormal

 Nonfatal stroke (year 1)

0.52

0.29–0.92

Lognormal

 Nonfatal stroke (beyond 1y)

0.52

0.29–0.92

Lognormal

 Coronary revascularization (year 1)

0.84

0.74–0.96

Lognormal

 Coronary revascularization (beyond 1y)

0.72

0.63–0.82

Lognormal

Intervention effect, rate ratio per 1mmol/l LDL-C reduction

 Nonfatal MI (year 1)

0.84

0.76–0.92

Lognormal

[4]

 Nonfatal MI (beyond 1y)

0.74

0.70–0.78

Lognormal

 Nonfatal stroke (year 1)

0.96

0.82–1.12

Lognormal

 Nonfatal stroke (beyond 1y)

0.81

0.74–0.88

Lognormal

 Coronary revascularization (year 1)

0.88

0.80–0.97

Lognormal

 Coronary revascularization (beyond 1y)

0.71

0.67–0.75

Lognormal

 Vascular causes of death

0.86

0·82 − 0·90

Lognormal

Annual cost of drugs, CNY

 Evolocumab (140 mg/2W)

7405

NA

NA

[28]

 Evolocumab (420 mg/M)

10365

NA

NA

[28]

 Statins

2855

2141.25–3568.75

Gamma

[28]

Cost of cardiovascular events, CNY

Direct cost

 Nonfatal MI (year 1)

26518.90

19889.18–33148.63

Gamma

[2]

 Nonfatal MI (beyond 1y)

13377.54

10033.15–16721.92

Gamma

[25]

 Nonfatal stroke (year 1)

12634.51

9475.88–15793.14

Gamma

[2]

 Nonfatal stroke (beyond 1y)

10141.98

7606.49–12677.48

Gamma

[27]

 Coronary revascularization

116279.90

87209.93–145349.88

Gamma

[2]

 Stroke + Post MI

13637.40

10228.05–17046.76

Gamma

[37]

 Death due to stroke

14063.87

10547.9–17579.83

Gamma

[27, 38]

 Death due to MI

22687.86

17015.89–28359.82

Gamma

[26, 39,40,41]

Indirect cost

 Nonfatal MI (year 1)

2037.44

1528.08–2546.8

Gamma

[2]

 Nonfatal stroke (year 1)

2629.56

1972.17–3286.95

Gamma

[2]

 Nonfatal stroke (beyond 1y)

13312.44

9984.33–16640.55

Gamma

[29]

 Coronary revascularization

5282.26

3961.69–6602.82

Gamma

[2]

 Stroke + Post MI

2766.90

2075.17–3458.62

Gamma

[37]

 Death due to stroke

3395.74

2546.81–4244.68

Gamma

[42]

 Death due to MI

2489.37

1867.03–3111.71

Gamma

[26, 39,40,41]

Utility

 Nonfatal MI (year 1)

0.866

0.847–0.886

Beta

[21, 33, 43]

 Nonfatal MI (beyond 1y)

0.950

0.942–0.958

Beta

[32, 33, 43]

 MI 2+(year 1)

0.819

0.793–0.846

Beta

[33, 43]

 MI 2+ (beyond 1y)

0.940

0.905–0.975

Beta

[32, 33, 43]

 Nonfatal stroke (year 1)

0.510

0.470–0.540

Beta

[34]

 Nonfatal stroke (beyond 1y)

0.750

0.710–0.800

Beta

[34, 44]

 Stroke 2+ (year 1)

0.340

0.320–0.360

Beta

[35]

 Stroke 2+ (beyond 1y)

0.420

0.390–0.451

Beta

[35]

 Injection site reaction, disutility

-0.0003

-0.002–0

Beta

[20]